Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
15 studies found for:    rucaparib
Show Display Options
Rank Status Study
1 Recruiting Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib
Condition: Solid Tumor
Interventions: Drug: C-14 labeled Rucaparib;   Drug: Rucaparib
2 Recruiting ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Conditions: Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: Chemotherapy;   Drug: Rucaparib
3 Recruiting A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Condition: Metastatic Castration Resistant Prostate Cancer
Intervention: Drug: Rucaparib
4 Active, not recruiting A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer;   Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
Intervention: Drug: Rucaparib
5 Completed A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Conditions: Pancreatic Cancer;   Pancreatic Ductal Adenocarcinoma
Intervention: Drug: Rucaparib
6 Not yet recruiting A Combination Study of Rucaparib and Atezolizumab in Participants With Solid Tumors and Advanced Gynecologic Cancers, With a Focus on Ovarian Cancer
Condition: Gynecologic Neoplasms
Interventions: Drug: Atezolizumab;   Drug: Rucaparib
7 Active, not recruiting A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Conditions: Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: Oral rucaparib
8 Recruiting A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature
Condition: Metastatic Breast Cancer
Intervention: Drug: rucaparib
9 Active, not recruiting A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: Rucaparib;   Drug: Placebo
10 Recruiting A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Condition: Metastatic Castration Resistant Prostate Cancer
Interventions: Drug: Rucaparib;   Drug: Abiraterone acetate or Enzalutamide or Docetaxel
11 Recruiting Pharmacokinetic Drug-Drug Interaction Study of Rucaparib
Condition: Neoplasms
Interventions: Drug: Caffeine;   Drug: Warfarin;   Drug: Omeprazole;   Drug: Midazolam;   Drug: digoxin;   Drug: Vitamin K;   Drug: Rucaparib
12 Completed A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens
Condition: Advanced Solid Tumors
Interventions: Drug: PF-01367338;   Drug: Carboplatin
13 Completed Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
Conditions: brca1 Mutation Carrier;   brca2 Mutation Carrier;   Breast Cancer;   Ovarian Cancer
Interventions: Drug: rucaparib (CO-338; formally AG-014699 or PF-01367338);   Genetic: protein expression analysis;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study
14 Withdrawn A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)
Conditions: Diabetes Mellitus;   Diabetic Retinopathy
Intervention: Drug: AG-014699
15 Active, not recruiting PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Condition: Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Rucaparib

Study has passed its completion date and status has not been verified in more than two years.